Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Microtek Drape Revenue Will Benefit From Revamped Sales Model – CEO

This article was originally published in The Gray Sheet

Executive Summary

Microtek Medical plans to maximize infection and fluid control drape sales growth by relying on a procedural-based marketing approach recently implemented by its sales force, according to President & CEO Dan Lee

You may also be interested in...



Microtek/IMP

Dip-molded medical device maker International Medical Products BV is acquired by Microtek May 28 from Cardinal Health, adding about $12 mil. in annual revenues. Microtek, which recorded 2003 revenue of $98.7 mil., notes the purchased product lines consist primarily of ultrasound probe covers and include cardiac thoracic drain systems, gynecological devices and wound care products. The move strengthens infection control offerings and expands European operations, Microtek says in a release...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel